• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Viridian Therapeutics Inc (NQ: VRDN )

    15.18 +0.30 (+2.02%)
    Streaming Delayed Price Updated: 2:33 PM EDT, Aug 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Viridian Therapeutics Inc

    < Previous 1 2 3 4 5 Next >
    Decoding 6 Analyst Evaluations For Viridian Therapeutics
    Via Benzinga
    VRDN Stock Earnings: Viridian Therapeutics Misses EPS, Misses Revenue for Q2 2024
    VRDN stock results show that Viridian Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Expert Ratings For Viridian Therapeutics
    Via Benzinga
    7 Analysts Assess Viridian Therapeutics: What You Need To Know
    Via Benzinga
    Unveiling 4 Analyst Insights On Viridian Therapeutics
    Via Benzinga
    Navigating 6 Analyst Ratings For Viridian Therapeutics
    Via Benzinga
    Top 3 Health Care Stocks You May Want To Dump This Quarter
    Via Benzinga
    Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
    Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
    Via Investor's Business Daily
    3 Small-Cap Stocks With Explosive 2X Growth Potential
    Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. 
    Via InvestorPlace
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics to Participate in Upcoming May Investor Conferences
    From Viridian Therapeutics, Inc.
    Via Business Wire
    VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024
    VRDN stock results show that Viridian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20
    Although cheap stocks under $20 represent a higher-risk profile, the rewards could be massive if the spotlight shines on them. 
    Via InvestorPlace
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Here's Why Viridian Therapeutics (VRDN) Stock Is Moving
    Viridian Therapeutics shares are trading lower by 5.9% Thursday morning. The company announced pricing of an underwritten public offering. 
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.